Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates

Overview

• US eye care drugmaker's Q3 product sales rose 64% yr/yr, beating analyst expectations

• Company posted Q3 net loss of $668.3 mln, reflecting acquisition-related R&D expenses

• Company appointed Neera Clase as Chief Commercial Officer

Outlook

• Tarsus expects topline data for TP-04 and TP-05 trials in first half of 2027

• Company plans to initiate Phase 3 IRX-101 study in first half of 2027, topline results in 2028

• Enrollment continues in Phase 3 Northstar trial for gildeuretinol; topline results expected in 2029

Result Drivers

• XDEMVY SALES GROWTH - Higher sales volume of XDEMVY, the only FDA-approved treatment for Demodex blepharitis, drove revenue growth

• PRESCRIBER BASE EXPANSION - More eye care professionals prescribed XDEMVY daily, supporting sales growth

• MARKETING INITIATIVES - Direct-to-consumer campaigns led to increased patient engagement and higher prescription conversion

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Tarsus Pharmaceuticals, Inc. is $102.00, about 39.1% above its November 2 closing price of $73.32

• The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 48 three months ago

Reuters Recommended Reads

• Nov 2 - Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

• Nov 3 - Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)